22 results
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
, the market for our products will depend significantly on access to third-party payers’ drug formularies or lists of medications for which third-party … access to a branded drug when a less costly generic equivalent or other alternative is available, even if not approved for the indications for which
8-K
EX-1.1
MIRA
Mira Pharmaceuticals Inc
7 Aug 23
MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial
5:14pm
in conformity with GAAP and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general … of the Company’s financial statements in conformity with GAAP and to maintain accountability for its assets, (c) access to the Company’s assets is permitted only
8-K
EX-4.1
MIRA
Mira Pharmaceuticals Inc
7 Aug 23
MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial
5:14pm
or rules of FINRA. Such investigation shall include access to books, records and properties and opportunities to discuss the business of the Company
424B4
MIRA
Mira Pharmaceuticals Inc
4 Aug 23
Prospectus supplement with pricing info
1:01pm
Act, a U.S. regulatory framework that governs the classification of certain substances, and therefore the market access available to such substances … financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, market corrections
424B1
m3133tlv4dg3i iz
4 Aug 23
Prospectus with pricing info
12:59pm
CORRESP
97zp9f47enqmhymjt
13 Jul 23
Correspondence with SEC
12:00am
S-1
EX-99.4
ixpa bfmjwbm
29 Jun 23
IPO registration
4:39pm
S-1
rji7u3ufzb kvhrg
29 Jun 23
IPO registration
4:39pm
S-1
EX-3.2
2ygi8 9wka1mmt5we6t
29 Jun 23
IPO registration
4:39pm
S-1
EX-14.1
zsjl8u1g0rbiel
29 Jun 23
IPO registration
4:39pm
DRS/A
nxga4e11j59knj
8 Jun 23
Draft registration statement (amended)
12:00am